Biopharm company focused on human monoclonal antibodies announced the closing of a EUR 27.5 million Series B round. The round was co-led by OrbiMed and Seventure Partners, with the existing shareholders Forbion Capital, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB also participating.
more...